Omeros (NASDAQ:OMER) Trading Down 3.1% – Should You Sell?

Omeros Co. (NASDAQ:OMER) traded down 3.1% during trading on Monday . The stock traded as low as $10.61 and last traded at $10.86. 44,701 shares traded hands during trading, a decline of 90% from the average session volume of 459,604 shares. The stock had previously closed at $11.21.

Wall Street Analysts Forecast Growth

OMER has been the topic of several analyst reports. RODMAN&RENSHAW raised shares of Omeros to a “strong-buy” rating in a research report on Thursday, November 14th. StockNews.com raised shares of Omeros from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Rodman & Renshaw started coverage on shares of Omeros in a report on Thursday, November 14th. They issued a “buy” rating and a $9.00 price objective for the company. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research report on Thursday, December 19th. Finally, D. Boral Capital assumed coverage on Omeros in a research note on Monday, December 23rd. They set a “buy” rating and a $36.00 target price for the company. Three analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.50.

Omeros Price Performance

The business has a 50 day moving average of $8.57 and a 200 day moving average of $5.73. The firm has a market capitalization of $573.13 million, a price-to-earnings ratio of -4.28 and a beta of 2.01.

Institutional Trading of Omeros

Several institutional investors have recently made changes to their positions in the business. BNP Paribas Financial Markets boosted its holdings in Omeros by 130.6% during the third quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 7,016 shares in the last quarter. MML Investors Services LLC lifted its position in shares of Omeros by 19.2% during the 3rd quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock worth $74,000 after buying an additional 3,000 shares during the period. SPC Financial Inc. acquired a new stake in Omeros in the 3rd quarter valued at $77,000. SG Americas Securities LLC bought a new stake in Omeros in the third quarter valued at $80,000. Finally, AQR Capital Management LLC acquired a new position in Omeros during the second quarter worth $105,000. 48.79% of the stock is currently owned by institutional investors and hedge funds.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.